中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Therapeutic drug monitoring of caffeine and its primary metabolites in plasma using LC-ESI-MS/MS for apnea of prematurity treatment: Evaluation of ultrapure water as a surrogate matrix

文献类型：期刊论文

作者Long, Jia-Yi1,2; Hu, Ya-Hui1; Xia, Ying1; Du, Fei-Fei3; Dai, Hao-Ran2; Tian, Man1; Xu, Jing1; Cheng, Rui4; Ding, Xuan-Sheng2; Guo, Hong-Li1
刊名BIOMEDICAL CHROMATOGRAPHY
出版日期2022-11
卷号36期号:11页码:e5462
ISSN号0269-3879
关键词apnea of prematurity caffeine LC-ESI-MS MS preterm infants surrogate matrix therapeutic drug monitoring
DOI10.1002/bmc.5462
文献子类Article
英文摘要The growing evidence has endorsed the view that therapeutic drug monitoring of caffeine for apnea of prematurity is helpful for dose tailoring when the therapeutic response is lacking or toxicity is suspected. However, plasma without caffeine is difficult to obtain. Therefore, a method was developed and validated to measure caffeine and its three primary metabolites (paraxanthine, theobromine and theophylline) using LC-ESI-MS/MS in human plasma and several surrogate matrices. The chromatographic separation of analytes was finally achieved on a Waters Symmetry C-18 (4.6 x 75 mm, 3.5 mu m) column. Several strategies were successfully applied to overcome the matrix effects: (a) appropriate dilution for sample cleanup; (b) a starting lower proportion of organic phase; and (c) multiple individual stable-labeled isotopic internal standards. The parallelism between the authentic matrix and surrogate matrices was convincing. The recovery of the analytes in both human plasma and rat plasma was acceptable over the linear range (0.500-50.0 mu g/ml for caffeine and 0.0100-1.00 mu g/ml for three metabolites). The method was successfully applied in 118 samples from 74 preterm infants with apnea of prematurity. The rat plasma or ultrapure water as a surrogate matrix is worthy of recommendation for routine therapeutic drug monitoring of caffeine.
WOS关键词PERFORMANCE ; CITRATE ; CYP1A2
WOS研究方向Biochemistry & Molecular Biology ; Chemistry ; Pharmacology & Pharmacy
语种英语
出版者WILEY
WOS记录号WOS:000837886500001
源URL[http://119.78.100.183/handle/2S10ELR8/309311]  
专题新药研究国家重点实验室
通讯作者Guo, Hong-Li; Chen, Feng
作者单位1.Nanjing Med Univ, Pharmaceut Sci Res Ctr, Dept Pharm, Childrens Hosp, Nanjing, Peoples R China;
2.China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing, Peoples R China;
3.Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai, Peoples R China;
4.Nanjing Med Univ, Neonatal Intens Care Unit, Childrens Hosp, Nanjing, Peoples R China
推荐引用方式
GB/T 7714		 Long, Jia-Yi,Hu, Ya-Hui,Xia, Ying,et al. Therapeutic drug monitoring of caffeine and its primary metabolites in plasma using LC-ESI-MS/MS for apnea of prematurity treatment: Evaluation of ultrapure water as a surrogate matrix[J]. BIOMEDICAL CHROMATOGRAPHY,2022,36(11):e5462.
APA Long, Jia-Yi.,Hu, Ya-Hui.,Xia, Ying.,Du, Fei-Fei.,Dai, Hao-Ran.,...&Chen, Feng.(2022).Therapeutic drug monitoring of caffeine and its primary metabolites in plasma using LC-ESI-MS/MS for apnea of prematurity treatment: Evaluation of ultrapure water as a surrogate matrix.BIOMEDICAL CHROMATOGRAPHY,36(11),e5462.
MLA Long, Jia-Yi,et al."Therapeutic drug monitoring of caffeine and its primary metabolites in plasma using LC-ESI-MS/MS for apnea of prematurity treatment: Evaluation of ultrapure water as a surrogate matrix".BIOMEDICAL CHROMATOGRAPHY 36.11(2022):e5462.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。